BeiGene, Ltd., an oncology company, engages in discovering and developing various treatments for cancer patients in the United States, China, Europe, and internationally. The company is headquartered in Camana Bay, the Cayman Islands.
| Revenue (TTM) | $6.13B |
| Gross Profit (TTM) | $5.45B |
| EBITDA | $1.07B |
| Operating Margin | 19.10% |
| Return on Equity | 14.70% |
| Return on Assets | 7.46% |
| Revenue/Share (TTM) | $55.27 |
| Book Value | $45.78 |
| Price-to-Book | 7.98 |
| Price-to-Sales (TTM) | 6.85 |
| EV/Revenue | 6.25 |
| EV/EBITDA | 33.66 |
| Quarterly Earnings Growth (YoY) | 166.70% |
| Quarterly Revenue Growth (YoY) | 29.60% |
| Shares Outstanding | $104.92M |
| Float | $80.96M |
| % Insiders | 17.28% |
| % Institutions | 33.29% |
Volatility is currently expanding
BeOne Medicines Ltd. - Sponsored ADR (ONC) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
KMX, ACIC, ONC, ODD and WES have been added to the Zacks Rank #1 (Strong Buy) List on October 15, 2026.
Biotech leader BeOne stock is poised to hit multiple buy points. Its blockbuster drug generated $1.2 billion in sales in the second quarter.
BeOne Medicines AG (ONC) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Trump's MFN push expands to nine mid-sized drugmakers, bringing 26 companies under agreements covering 89% of the branded drug market.
SAN CARLOS, Calif.--(BUSINESS WIRE)---- $ONC #BeOne--BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced it will participate in the Morgan Stanley Annual Global Healthcare Conference on September 14, 2026, with a fireside chat at 11:30 a.m. EDT. The live webcast of this event can be accessed from the investors section of the Company's website at https://ir.beonemedicines.com. An archived webcast will be available on the Company's website. About BeOne Medicin.
SAN CARLOS, Calif.--(BUSINESS WIRE)---- $ONC #BeOne--BeOne Medicines, Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced a voluntary agreement with the U.S. Government to expand access to innovative cancer medicines for American patients while strengthening our U.S manufacturing footprint and further expanding the capabilities needed to deliver medicines at scale. The agreement builds on BeOne's longstanding commitment to patient access and investment in research and scien.
SAN CARLOS, Calif.--(BUSINESS WIRE)---- $ONC #BeOne--BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced positive topline results from the second interim analysis (IA2) of the Phase 3 HERIZON-GEA-01 trial evaluating ZIIHERA® (zanidatamab), in combination with chemotherapy, with and without TEVIMBRA® (tislelizumab), as first-line treatment for HER2+ locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). At IA2, ZIIHERA plus chemotherapy demonst.
Does BeOne Medicines Ltd. - Sponsored ADR (ONC) have what it takes to be a top stock pick for momentum investors?
BeOne Medicines Ltd. - Sponsored ADR (ONC) reached a significant support level, and could be a good pick for investors from a technical perspective.
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on ONC and any ticker you trade — then tracks every position and per-strategy win rate.
